• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Genenta Science S.p.A.

    5/29/26 4:05:07 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2026

     

    Commission File Number: 001-41115

     

    GENENTA SCIENCE S.P.A.

    (Translation of registrant’s name into English)

     

    Via dell’Annunciata 31

    20121 Milan, Italy

    (Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    This report on Form 6-K, including Exhibit 10.1, is incorporated by reference into the registrant’s (i) registration statement on Form F-3 (File No. 333-271901) and (ii) registration statement on Form S-8 (File No. 333-278392).

     

     

     

     

     

     

    Other Events

     

    A.T.C. Amendment Agreement

     

    As previously disclosed in the Current Report on Form 6-K of Genenta Science S.p.A. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 27, 2026, the Company previously entered into an Investment Agreement with A.T.C. S.r.l. (“A.T.C.”) on January 24, 2026 (the “Investment Agreement”). On May 25, 2026, the Company entered into an amendment to the Investment Agreement (as amended, the “A.T.C. Amendment Agreement”), pursuant to which the Company committed to acquire the remaining 80.5% equity ownership in A.T.C. from Marco Spiga, Mattia Berardinetti, and Gioacchino Specchi (collectively, the “A.T.C. Shareholders”). The acquisition of such equity ownership pursuant to the A.T.C. Amendment Agreement (the “Transaction”) was completed on May 29, 2026, before the Italian Notary. The principal economic terms of the Transaction, including the aggregate purchase price and the Purchase Price per Share (as defined below), were approved by the Company’s Board of Directors on May 18, 2026. The key terms of the Transaction are as follows:

     

    ●The aggregate purchase price for the Company’s acquisition of the 80.5% equity ownership in A.T.C. from the A.T.C. Shareholders was Euro 9,604,076.82 and was paid by the Company by way of set-off against the amount owed by the A.T.C. Shareholders to the Company in connection with the subscription by the A.T.C. Shareholders of no. 24,625,838 ordinary shares of the Company, no par value (the “Ordinary Shares”), at a subscription price per share equal to Euro 0.39 (the “Purchase Price per Share”). The Ordinary Shares were allotted to the A.T.C. Shareholders in proportion to their respective pro-rata portion of the aggregate purchase price.

     

    ●The Ordinary Shares allotted to the A.T.C. Shareholders shall be subject to a lock-up period of 36 months commencing from the date of issuance (the “Lock-Up Period”). Moreover, for the duration of the Lock-Up Period, the A.T.C. Shareholders shall not, directly or indirectly, purchase or promise to purchase any shares or securities of the Company or rights convertible into or exchangeable for, or any derivatives however related to, any shares or other securities of the Company. In addition, for the duration of the Lock-Up Period, the A.T.C. Shareholders have waived their right to enroll in the Company’s loyalty share program, or to request access to any enhanced voting rights associated with the Ordinary Shares.

     

    ●The A.T.C. Shareholders have been granted a put option, exercisable from the third anniversary of the issuance of the Ordinary Shares and ending on the fifth anniversary thereof (the “Put Option”). Pursuant to the Put Option, if in any calendar quarter during such period, the volume-weighted average price of the Ordinary Shares, calculated on the basis of the official quotations of the preceding three months, is lower than the Purchase Price per Share by more than 30% (the “Floor Price”), each A.T.C. Shareholder shall have the right to sell to the Company all or part of the Ordinary Shares held by such A.T.C. Shareholder at a price per share equal to the Floor Price. The Put Option may be exercised within 15 days following the end of the relevant calendar quarter. Upon exercise of the Put Option, the Company shall have the right to (i) acquire directly the Ordinary Shares for which the Put Option has been exercised, (ii) designate a third-party to acquire the Ordinary Shares for which the Put Option has been exercised, or (iii) to initiate a search procedure to identify a potential third-party purchaser interested in acquiring the Ordinary Shares for which the Put Option has been exercised, provided that such procedure shall be completed within three calendar months from receipt of the applicable exercise notice.

     

    ●Notwithstanding the lock-up, the Company has been granted a call option, exercisable from the first anniversary of the issuance of the Ordinary Shares and ending on the third anniversary thereof (the “Call Option”). Pursuant to the Call Option, if in any calendar quarter during such period, the volume-weighted average price of the Ordinary Shares, calculated based on the official quotations of the preceding three months, is higher than the Purchase Price per Share by more than 30%, the Company shall have the right to purchase from each A.T.C. Shareholder all or part of the Ordinary Shares held by such A.T.C. Shareholder at a price per share equal to the Purchase Price per Share, plus 30%. The Call Option may be exercised within 15 days following the end of the relevant calendar quarter. Upon exercise of the Call Option, the Company shall have the right to (i) acquire directly the Ordinary Shares for which the Call Option has been exercised, (ii) designate a third-party to acquire the Ordinary Shares for which the Call Option has been exercised, or (iii) to initiate a search procedure to identify a potential third-party purchaser interested in acquiring the Ordinary Shares for which the Call Option has been exercised, provided that such procedure shall be completed within three calendar months from issuance of the applicable exercise notice.

     

    ●The Transaction is not intended to create a “group” within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), among the A.T.C. Shareholders for the purpose of acquiring, holding, voting or disposing of securities of the Company. Each A.T.C. Shareholder shall be solely responsible for its own beneficial ownership reporting obligations under the Exchange Act.

     

    ●None of the A.T.C. Shareholders have any right to nominate candidates for, or seek appointment to, the Company’s board of directors, and shall not enter into any employment, consulting, or management agreement with the Company.

     

    The foregoing description of the A.T.C Amendment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the A.T.C. Amendment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 6-K (this “Report”) and is incorporated by reference herein.

     

    Forward-Looking Statements

     

    This Report contains forward-looking statements that involve risks and uncertainties, such as statements regarding the Company’s acquisition of equity ownership in A.T.C.

     

    The risks and uncertainties involved include the Company’s and the A.T.C. Shareholders’ ability to satisfy and comply with the provisions contained in the Agreement, including but not limited to the Lock-Up Period, the Put Option, the Call Option, market conditions, and other risks detailed from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company’s current expectations and assumptions and speak only as of the date of this Report. The Company does not intend to revise or update any forward-looking statement in this Report as a result of new information, future events or otherwise, except as required by law.

     

     

     

     

    SUBMITTED HEREWITH

     

    Attached to this Report for the month of June 2026, and incorporated by reference herein, is:

     

    Exhibits.

     

    Exhibit No.   Description
    10.1*   Amendment to the Investment Agreement, dated May 25, 2026, by and among the Company, A.T.C. S.r.l., Marco Spiga, Mattia Berardinetti, and Gioacchino Specchi.

     

     * Certain portions of this exhibit (indicated with “[***]”) have been redacted in accordance with Item 601(b)(10)(iv) of Regulation S-K. Certain annexes, schedules, and exhibits have also been omitted pursuant to Item 601(a)(5) of Regulation S-K.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      GENENTA SCIENCE S.P.A.
         
      By: /s/ Pierluigi Paracchi
      Name:  Pierluigi Paracchi
      Title: Chief Executive Officer

     

    Dated: May 29, 2026

     

     

     

    Get the next $GNTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    SEC Filings

    View All

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    5/29/26 4:05:07 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    5/19/26 5:08:11 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    4/28/26 4:05:02 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Paracchi Pierluigi

    4 - Genenta Science S.p.A. (0001838716) (Issuer)

    5/5/26 9:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Paracchi Giacomoantonio

    4 - Genenta Science S.p.A. (0001838716) (Issuer)

    4/1/26 4:05:24 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Galimi Francesco

    4 - Genenta Science S.p.A. (0001838716) (Issuer)

    4/1/26 4:05:27 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genenta signs Definitive Agreements with Sophia High Tech

    MILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has signed definitive agreements2 with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs. Genenta expects to fund a total of €6.0 million in two tranches. With the closing of the first tranche, Genenta will obtain a 19.9% stake, and with the closing of the second tranche, Genenta will own a 51% stake in Sòphia HT. The proceeds are expected to be deploy

    4/23/26 7:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

    MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has entered into a binding offer with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs, under which Genenta will fund Sòphia through two reserved capital increases, with the goal of reaching a controlling stake upon the achievement of defined performance milestones. The transaction with Sòphia High Tech would be completed in two phases and remains subject to

    3/27/26 5:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

    MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that, with respect to its biotechnology platform, Genenta has been and continues to be actively engaged with DC Advisory to explore potential collaboration opportunities for the further development of its original biotechnology platform, which originated from research conducted by founder-scientists, Professor Luigi Naldini and Bernhard Gentner. To date, DC Advisory has not identified, and the Company is not in any active discussions with,

    3/24/26 3:26:56 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

    ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

    6/29/23 9:11:48 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

    H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

    7/25/22 7:15:53 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Leadership Updates

    Live Leadership Updates

    View All

    Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

    MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group

    2/27/26 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

    Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

    1/8/25 3:17:00 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

    MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

    5/6/24 6:25:00 AM ET
    $ARYD
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/12/24 4:05:34 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/10/23 6:02:50 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Genenta Science S.p.A.

    SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

    2/25/22 1:17:49 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care